Key clinical point: A retrospective study suggests the incidence and severity of hypertension is considerably higher in patients with B-cell malignancies treated with ibrutinib.
Major finding: After a median follow-up of 30 months, 78.3% of patients treated with ibrutinib experienced new or worsening hypertension.
Study details: A retrospective analysis of 562 consecutive patients with a lymphoid malignancy who received ibrutinib.
Disclosures: The study was funded by the National Institutes of Health, the D. Warren Brown Family Foundation, the Four Winds Foundation, and the Connie Brown CLL Research Fund. The authors reported financial affiliations with Janssen, Pharmacyclics, and other companies.
Dickerson T et al. Blood. 2019 Oct 3. doi: 10.1182/blood.2019000840.